Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 36, 2006 - Issue 12
Submit an article Journal homepage
106
Views
5
CrossRef citations to date
0
Altmetric
Original

Glucuronidation in the chimpanzee (Pan troglodytes): Studies with acetaminophen, oestradiol and morphine

H. Wong Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USACorrespondence[email protected]
,
H. Wong Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USACorrespondence[email protected]
,
J. E. Grace Jr Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
M. R. Wright Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
H. Wong Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USACorrespondence[email protected]
,
J. E. Grace Jr Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
M. R. Wright Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
M. R. Browning Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
S. J. Grossman Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
S. A. Bai Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
H. Wong Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USACorrespondence[email protected]
,
J. E. Grace Jr Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
M. R. Wright Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
M. R. Browning Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
S. J. Grossman Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
S. A. Bai Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
D. D. Christ Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
H. Wong Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USACorrespondence[email protected]
,
J. E. Grace Jr Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
M. R. Wright Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
M. R. Browning Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
S. J. Grossman Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
,
S. A. Bai Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
&
D. D. Christ Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Co., Wallingford, CT, Wilmington, DE, Princeton, NJ and Newark, DE, USA
 show all
Pages 1178-1190 | Received 10 Jun 2006, Accepted 15 Jul 2006, Published online: 11 Aug 2009
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

The chimpanzee has recently been characterized as a surrogate for oxidative drug metabolism in humans and as a pharmacokinetic model for the selection of drug candidates. In the current study, the glucuronidation of acetaminophen, morphine and oestradiol was evaluated in the chimpanzee to extend the characterization of this important animal model. Following oral administration of acetaminophen (600 mg) to chimpanzees (n = 2), pharmacokinetics were comparable with previously reported human values, namely mean oral clearance 0.91 vs. 0.62 ± 0.05 l h−1 kg−1, apparent volume of distribution 2.29 vs. 1.65 ± 0.25 l kg−1, and half-life 1.86 vs. 1.89 ± 0.27 h, for chimpanzee vs. human, respectively. Urinary excretions (percentage of dose) of acetaminophen, acetaminophen glucuronide and acetaminophen sulfate were also similar between chimpanzees and humans, namely 2.3 vs. 5.0, 63.1 vs. 54.7, and 25.0 vs. 32.3%, respectively. Acetaminophen, oestradiol and morphine glucuronide formation kinetics were investigated using chimpanzee (n = 2) and pooled human liver microsomes (n = 10). and (or ) for acetaminophen glucuronide, morphine 3- and 6-glucuronide, and oestradiol 3- and 17-glucuronide formation were comparable in both species. Eadie–Hofstee plots of oestradiol 3-glucuronide formation in chimpanzee microsomes were characteristic of autoactivation kinetics. Western immunoblot analysis of chimpanzee liver microsomes revealed a single immunoreactive band when probed with anti-human UGT1A1, anti-human UGT1A6, and anti-human UGT2B7. Taken collectively, these data demonstrate similar glucuronidation characteristics in chimpanzees and humans.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Use of In Vivo Animal Models to Assess Pharmacokinetic Drug-Drug Interactions
Source: Springer Science and Business Media LLC

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.